Zenas BioPharma (NASDAQ:ZBIO) Upgraded to Hold at Wall Street Zen

Zenas BioPharma (NASDAQ:ZBIO) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

ZBIO has been the subject of a number of other research reports. Citigroup raised their price target on shares of Zenas BioPharma from $27.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $48.00 price target on shares of Zenas BioPharma in a research note on Tuesday, January 6th. Morgan Stanley cut Zenas BioPharma from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $37.00 to $19.00 in a research report on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a report on Monday, December 29th. Finally, HC Wainwright restated a “buy” rating and issued a $44.00 target price on shares of Zenas BioPharma in a research note on Tuesday, February 10th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $43.14.

Zenas BioPharma Trading Down 4.2%

Shares of ZBIO stock opened at $25.88 on Friday. The firm has a fifty day moving average of $26.26 and a 200-day moving average of $25.95. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -3.66 and a beta of -1.50. Zenas BioPharma has a 52-week low of $6.11 and a 52-week high of $44.60. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66.

Insiders Place Their Bets

In other Zenas BioPharma news, Director Patricia L. Allen purchased 15,700 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The stock was acquired at an average cost of $24.85 per share, with a total value of $390,145.00. Following the completion of the acquisition, the director directly owned 15,700 shares of the company’s stock, valued at $390,145. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Hongbo Lu acquired 25,985 shares of the firm’s stock in a transaction on Wednesday, February 11th. The shares were bought at an average cost of $22.50 per share, for a total transaction of $584,662.50. Following the acquisition, the director owned 347,968 shares in the company, valued at approximately $7,829,280. The trade was a 8.07% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have acquired 202,845 shares of company stock valued at $3,747,185. 16.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zenas BioPharma

A number of large investors have recently modified their holdings of the stock. Quarry LP grew its stake in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the last quarter. Russell Investments Group Ltd. bought a new position in Zenas BioPharma in the 3rd quarter valued at $30,000. GF Fund Management CO. LTD. bought a new position in Zenas BioPharma in the 4th quarter valued at $38,000. BNP Paribas Financial Markets increased its stake in shares of Zenas BioPharma by 120.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after buying an additional 1,716 shares during the period. Finally, CWM LLC raised its position in shares of Zenas BioPharma by 48.3% during the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after acquiring an additional 709 shares during the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.